The tumor-modulatory effects of Caspase-2 and Pidd1 do not require the scaffold protein Raidd

Cell Death and Differentiation

Volumn 22, Issue 11, 2015, Pages 1803-1811

  Peintner, L ^a   Dorstyn, L ^b   Kumar, S ^b   Aneichyk, T ^a   Villunger, A ^a   Manzl, C ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 2; CRADD PROTEIN; DNA; HISTONE H3; MYC PROTEIN; PIDD1 PROTEIN; PROTEIN P53; TUMOR PROMOTER; UNCLASSIFIED DRUG; CRADD PROTEIN, MOUSE; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; LRDD PROTEIN, MOUSE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CONTROLLED STUDY; DNA DAMAGE; EMBRYO; GENE ACTIVATION; GENE OVEREXPRESSION; GENOMIC INSTABILITY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; THYMUS LYMPHOMA; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL CYCLE; CELL SURVIVAL; DRUG EFFECTS; FIBROSARCOMA; GENETICS; METABOLISM; RADIATION RESPONSE;

ANIMALS; CASPASE 2; CELL CYCLE; CELL SURVIVAL; CELLS, CULTURED; CRADD SIGNALING ADAPTOR PROTEIN; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEINS; DNA DAMAGE; FIBROSARCOMA; MICE; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84943198640     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2015.31     Document Type: Article

References (53)

1. McIlwain DR, Berger T, Mak TW. Caspase functions in cell death and disease. Cold Spring Harbor Perspect Biol 2013; 5: 4.
2. Puccini J, Dorstyn L, Kumar S. Caspase-2 as a tumour suppressor. Cell Death Differ 2013; 20: 1133-1139.
3. Ho LH, Taylor R, Dorstyn L, Cakouros D, Bouillet P, Kumar S. A tumor suppressor function for caspase-2. Proc Natl Acad Sci USA 2009; 106: 5336-5341.
4. Manzl C, Peintner L, Krumschnabel G, Bock F, Labi V, Drach M et al. PIDDosomeindependent tumor suppression by Caspase-2. Cell Death Differ 2012; 19: 1722-1732.
5. Parsons MJ, McCormick L, Janke L, Howard A, Bouchier-Hayes L, Green DR. Genetic deletion of caspase-2 accelerates MMTV/c-neu-driven mammary carcinogenesis in mice. Cell Death Differ 2013; 20: 1174-1182.
6. Puccini J, Shalini S, Voss AK, Gatei M, Wilson CH, Hiwase DK et al. Loss of caspase-2 augments lymphomagenesis and enhances genomic instability in Atm-deficient mice. Proc Natl Acad Sci USA 2013; 110: 19920-19925.
7. Terry MR, Arya R, Mukhopadhyay A, Berrett KC, Clair PM, Witt B et al. Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo. Cell Death Differ 2015; 22: 719-730.
8. Kumar S, White D, Takai S, Tuczynowicz S, Juttner C, Hughes T. Apoptosis regulatory gene NEDD2 maps to human chromosome segment 7q34-35, a region fequently affected in haematological neoplasms. Hum Genet 1995; 95: 641-644.
9. Estrov Z, Thall PF, Talpaz M, Estey EH, Kantarjian HM, Andreeff M et al. Caspase 2 and Caspase 3 protein levels as predictors of survival in acute myelogenous leukemia. Blood 1998; 92: 3090-3097.
10. Hofmann WK, de Vos S, Tsukasaki K, Wachsman W, Pinkus G, Said J et al. Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 2001; 98: 787-794.
11. Holleman A, MLd Boer, Kazemier KM, Beverloo HB, von Bergh ARM, Janka-Schaub GE et al. Decreased PARP and procaspase-2 protein levels are associated with cellular drug resistance in childhood acute lymphoblastic leukemia. Blood 2005; 106: 1817-1823.
12. Kim MS, Kim HS, Jeong EG, Soung YH, Yoo NJ, Lee SH. Somatic mutations of caspase-2 gene in gastric and colorectal cancers. Pathol Res Pract 2011; 207: 640-644.
13. Ren K, Lu J, Porollo A, Du C. Tumor-suppressing Function of Caspase-2 Requires Catalytic Site Cys-320 and Site Ser-139 in Mice. J Biol Chem 2012; 287: 14792-14802.
14. Colussi PA, Harvey NL, Kumar S. Prodomain-dependent Nuclear Localization of the Caspase-2 (Nedd2) Precursor: A NOVEL FUNCTION FOR A CASPASE PRODOMAIN. J Biol Chem 1998; 273: 24535-24542.
15. Butt AJ, Harvey NL, Parasivam G, Kumar S. Dimerization and Autoprocessing of the Nedd2 (Caspase-2) Precursor Requires both the Prodomain and the Carboxyl-terminal Regions. J Biol Chem 1998; 273: 6763-6768.
16. Baliga BC, Read SH, Kumar S. The biochemical mechanism of caspase-2 activation. Cell Death Differ 2004; 11: 1234-1241.
17. Krumschnabel G, Sohm B, Bock F, Manzl C, Villunger A. The enigma of caspase-2: the laymen's view. Cell Death Differ 2009; 16: 195-207.
18. Krumschnabel G, Manzl C, Villunger A. Caspase-2: killer, savior and safeguard-emerging versatile roles for an ill-defined caspase. Oncogene 2009; 28: 3093-3096.
19. Tinel A, Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 2004; 304: 843-846.
20. Bock FJ, Peintner L, Tanzer M, Manzl C, Villunger A. P53-induced protein with a death domain (PIDD): master of puppets. Oncogene 2012; 31: 4733-4739.
21. Duan H, Dixit V. RAIDD is a new 'death' adaptor molecule. Nature 1997; 238: 86-89.
22. Zhou P, Chou J, Olea R, Yuan J, Wagner G. Solution structure of Apaf-1 CARD and its interaction with caspase-9 CARD-a structural basis for specific adaptor-caspase interaction. Proc Natl Acad Sci USA 1999; 96: 11265-11270.
23. Lin Q, Liu Y, Moore DJ, Elizer SK, Veach RA, Hawiger J et al. Cutting edge: the 'death' adaptor CRADD/RAIDD targets BCL10 and suppresses agonist-induced cytokine expression in T lymphocytes. J Immunol 2012; 188: 2493-2497.
24. Qiao H, Liu Y, Veach RA, Wylezinski L, Hawiger J. The Adaptor CRADD/RAIDD Controls Activation of Endothelial Cells by Proinflammatory Stimuli. J Biol Chem 2014; 289: 21973-21983.
25. Yang C, Hornicek FJ,Wood KB, Schwab JH, Mankin H, Duan Z. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines. Cancer Chemother Pharmacol 2009; 64: 607-614.
26. Hasegawa H, Yamada Y, Tsukasaki K, Mori N, Tsuruda K, Sasaki D et al. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 2011; 25: 575-587.
27. Mahoney D, Lefebvre C, Allan K, Brun J, Sanaei C, Baird S et al. Virus-tumor interactome screen reveals ER stress response can reprogram resistant cancers for oncolytic virustriggered Caspase-2 cell death. Cancer Cell 2011; 20: 443-456.
28. Janssens S, Tinel A, Lippens S, Tschopp J. PIDD mediates NF-kappaB activation in response to DNA damage. Cell 2005; 123: 1079-1092.
29. Matheu A, Maraver A, Klatt P, Flores I, Garcia-Cao I, Borras C et al. Delayed ageing through damage protection by the Arf/p53 pathway. Nature 2007; 448: 375-379.
30. Harris AW, Pinkert CA, Crawford M, Langdon WY, Brinster RL, Adams JM. The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells. J Exp Med 1988; 167: 353-371.
31. Michalak EM, Jansen ES, Happo L, Cragg MS, Tai L, Smyth GK et al. Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 2009; 16: 684-696.
32. Frenzel A, Labi V, Chmelewskij W, Ploner C, Geley S, Fiegl H et al. Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. Blood 2010; 115: 995-1005.
33. Sochalska M, Tuzlak S, Egle A, Villunger A. Lessons from gain-and loss-of-function models of pro-survival Bcl2 family proteins: implications for targeted therapy. FEBS J 2015; 282: 834-849.
34. Adams J, Harris A, Pinkert C, Corcoran L, Alexander W, Cory S et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 1985; 318: 533-538.
35. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 2004; 101: 6164-6169.
36. Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev 1999; 13: 2658-2669.
37. Dorstyn L, Puccini J, Wilson CH, Shalini S, Nicola M, Moore S et al. Caspase-2 deficiency promotes aberrant DNA-damage response and genetic instability. Cell Death Differ 2012; 19: 1288-1298.
38. Fava LL, Bock FJ, Geley S, Villunger A. Caspase-2 at a glance. J Cell Sci 2012; 125: 5911-5915.
39. Bric A, Miething C, Bialucha CU, Scuoppo C, Zender L, Krasnitz A et al. Functional identification of tumor suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16: 324-335.
40. Oliver TG, Meylan E, Chang GP, Xue W, Burke JR, Humpton TJ et al. Caspase-2-mediated cleavage of Mdm2 creates a p53-induced positive feedback loop. Mol Cell 2011; 43: 57-71.
41. Sohn D, Budach W, Janicke RU. Caspase-2 is required for DNA damage-induced expression of the CDK inhibitor p21(WAF1/CIP1). Cell Death Differ 2011; 18: 1664-1674.
42. Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW. The role of p21waf1/cip1 and p27Kip1 in HDACi-mediated tumor cell death and cell cycle arrest in the E?-myc model of B-cell lymphoma. Oncogene 2014; 33: 5415-5423.
43. Manzl C, Fava LL, Krumschnabel G, Peintner L, Tanzer MC, Soratroi C et al. Death of p53-defective cells triggered by forced mitotic entry in the presence of DNA damage is not uniquely dependent on Caspase-2 or the PIDDosome. Cell Death Dis 2013; 4: e942.
44. O'Reilly L, Ekert P, Harvey N, Mardsen V, Cullen L, Vaux D et al. Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death Differ 2002; 9: 832-841.
45. Berube C, Boucher LM, MaW,Wakeham A, Salmena L, Hakem R et al. Apoptosis caused by p53-induced protein with death domain (PIDD) depends on the death adapter protein RAIDD. Proc Natl Acad Sci USA 2005; 102: 14314-14320.
46. Garcia-Cao I, Garcia-Cao M, Martin-Caballero J, Cridao LM, Klatt P, Flores JM et al. 'Super p53' mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J 2002; 21: 6225-6235.
47. Elowe S, Dulla K, Uldschmid A, Li X, Dou Z, Nigg EA. Uncoupling of the spindle-checkpoint and chromosome-congression functions of BubR1. J Cell Sci 2010; 123: 84-94.
48. Gentleman R, Carey V, Bates D, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
49. Rainer J, Lelong J, Bindreither D, Mantinger C, Ploner C, Geley S et al. Research resource: transcriptional response to glucocorticoids in childhood acute lymphoblastic leukemia. Mol Endocrinol 2012; 26: 178-193.
50. Bindreither D, Ecker S, Gschirr B, Kofler A, Kofler R, Rainer J. The synthetic glucocorticoids prednisolone and dexamethasone regulate the same genes in acute lymphoblastic leukemia cells. BMC Genomics 2014; 15: 662.
51. Wu Z, Irizarry RA, Gentleman R, Martinez-Murillo F, Spencer F. A model-based background adjustment for oligonucleotide expression arrays. J Am Stat Association 2004; 99: 909-917.
52. Smyth GK. Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: 29.
53. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B (Methodol) 1995; 57: 289-300.